CSL secures lixudebart licensing deal with Alentis for 355 million dollars
Biopharmaceutical firm CSL paid 355 million US dollars upfront to Alentis to commercialise lixudebart pledging up to 1 2 billion US dollars in milestone payments for rare disease therapies
Melbourne, Australia and Basel, Switzerland - CSL and Alentis Therapeutics have entered an exclusive global collaboration to develop and promote lixudebart, a potential first-in-class therapy targeting claudin-1 in kidney, liver, and other diseases. Lixudebart is currently being evaluated in the ongoing Phase 2 RENAL trial for ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), a rare and life-threatening autoimmune disease that can cause irreversible kidney damage.
The collaboration combines Alentis' expertise in claudin-1 targeting with CSL's global development and commercialisation capabilities in nephrology. The partnership aims to accelerate lixudebart's development in various indications, including focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC). CSL will invest US$355 million initially, with up to US$1.2 billion in potential commercial milestone payments.
The companies will jointly fund the completion of the Phase 2 RENAL trial, planned Phase 3 trial in AAV-RPGN, Phase 2 trials in FSGS and PSC, and other development activities. Global profits will be shared 55% to CSL and 45% to Alentis.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
